Paivi K. Auvinen

Kuopio, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies.

Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies.

Journal: Journal of the National Cancer Institute

Published: February 25, 2026

Malignant vs. Non-malignant Annotations on TCGA Breast Cancer Whole Slide Images for AI Analysis.

Malignant vs. Non-malignant Annotations on TCGA Breast Cancer Whole Slide Images for AI Analysis.

Journal: Scientific data

Published: October 09, 2025

Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland.

Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 05, 2025

Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.

Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.

Journal: The Journal of pathology

Published: July 09, 2025

Gut microbiota-derived extracellular vesicles form a distinct entity from gut microbiota.

Gut microbiota-derived extracellular vesicles form a distinct entity from gut microbiota.

Journal: mSystems

Published: April 29, 2025

Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy - an observational, multicenter study.

Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy - an observational, multicenter study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 23, 2025

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.

Journal: Clinical breast cancer

Published: April 01, 2025

The metabolome of fecal extracellular vesicles in patients with malignant solid tumors.

The metabolome of fecal extracellular vesicles in patients with malignant solid tumors.

Journal: Scientific reports

Published: March 28, 2025

Nonadherence to changing guidelines in early breast cancer over two decades.

Nonadherence to changing guidelines in early breast cancer over two decades.

Journal: BMC cancer

Published: November 30, 2024

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Journal: JAMA network open

Published: August 26, 2024

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

Journal: American journal of human genetics

Published: March 29, 2024

High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer.

High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer.

Journal: Cancers

Published: December 28, 2023

Showing 1-12 of 76

Last Updated: 09/26/2026